EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Antonio
Llombart Cussac
Publicaciones en las que colabora con Antonio Llombart Cussac (10)
2024
2021
-
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255
-
The role of CDK4/6 inhibitors in early breast cancer
Breast, Vol. 58, pp. 160-169
2020
-
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1455-1464
-
A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428
-
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Nature Communications, Vol. 11, Núm. 1
-
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 33-43
2019
2009
-
Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer
Journal of Clinical Oncology, Vol. 27, Núm. 4, pp. 526-534
2006
-
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: Efficacy and correlation with HER2 extracellular domain
Clinical and Translational Oncology, Vol. 8, Núm. 12, pp. 896-902